SpringWorks Therapeutics, Inc

(NASDAQ:SWTX)

Latest On SpringWorks Therapeutics, Inc (SWTX):

Date/Time Type Description Signal Details
2023-05-03 15:49 ESTNewsSpringWorks Therapeutics GAAP EPS of -$1.18 beats by $0.07N/A
2023-04-14 17:15 ESTNewsSpringWorks Therapeutics: Pfizer Offshoot With Interesting PipelineN/A
2023-04-09 21:40 ESTNewsPremier cancer research event, AACR is starting this week; Here is what to expectN/A
2023-02-28 10:05 ESTNewsSpringWorks Therapeutics GAAP EPS of -$5.21 beats by $0.04N/A
2023-02-27 20:05 ESTNewsSpringWorks wins FDA priority review for lead candidateN/A
2022-12-27 12:28 ESTNewsSpringWorks seeks FDA approval of nirogacestat for desmoid tumorsN/A
2022-11-03 15:54 ESTNewsSpringWorks Therapeutics GAAP EPS of -$1.37 misses by $0.05N/A
2022-09-08 01:14 ESTNewsSpringWorks expands license deal with GSK for myeloma combo, to get $75M investmentN/A
2022-08-10 23:57 ESTNewsSpringWorks drops 21% as Allogene drops lead asset in combination studyN/A
2022-08-04 17:17 ESTNewsSpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15N/A
2022-07-21 02:58 ESTNewsSizing Up SpringWorks TherapeuticsN/A
2022-05-27 09:58 ESTNewsSpringWorks plunges after announcing trial data for lead asset in multiple myelomaN/A
2022-05-25 03:27 ESTNewsSpringWorks falls after announcing late-stage data for lead asset in desmoid tumorsN/A
2022-05-25 03:27 ESTNewsSpringWorks price target raised at Goldman Sachs after trial win for lead assetsN/A
2022-05-05 10:54 ESTNewsSpringWorks Therapeutics GAAP EPS of -$1.26 misses by $0.21N/A
2022-05-03 02:55 ESTNewsSpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data ReleasesN/A
2022-02-24 19:57 ESTNewsSpringWorks Therapeutics GAAP EPS of -$1.15N/A
2022-01-13 04:59 ESTNewsSpringWorks Therapeutics (SWTX) Presents At 40th Annual J.P. Morgan Virtual Healthcare ConferenceN/A
2021-12-14 22:23 ESTNewsSpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug PipelineN/A
2021-12-10 22:54 ESTNewsSpringWorks teams up with AbbVie to evaluate nirogacestat + ABBV-383 in multiple myelomaN/A
2021-11-04 16:57 ESTNewsSpringWorks Therapeutics EPS misses by $0.08N/A
2021-10-28 03:22 ESTNewsSpringWorks Therapeutics and GlaxoSmithKline provide update on collaboration agreementN/A
2021-10-20 16:10 ESTNewsSpringWorks Therapeutics inks research collaboration agreementsN/A
2021-10-12 13:35 ESTNewsWarning: SWTX is at high risk of performing badlyN/A
2021-10-06 18:11 ESTNewsSWTX is at high risk of performing badlyN/A
2021-09-29 01:08 ESTNewsWarning: SWTX has been downgraded to Very BearishN/A
2021-08-30 19:46 ESTNewsSpringWorks inks research collaboration to study nirogacestat in multiple myelomaN/A
2021-08-04 15:57 ESTNewsSpringWorks Therapeutics EPS misses by $0.30N/A
2021-08-03 19:07 ESTNewsSpringWorks Therapeutics to initiate early-stage mirdametinib cancer studyN/A
2021-07-27 16:54 ESTNewsSpringWorks Therapeutics names James Cassidy as chief medical officerN/A
2021-07-22 02:53 ESTNewsSpringWorks teams up with Seagen to evaluate nirogacestat combo in multiple myelomaN/A
2021-07-22 02:46 ESTNewsSpringWorks shows durable effect for neurofibroma therapy with long-term dataN/A
2021-07-22 02:45 ESTNewsSpringWorks Therapeutics launches Phase 1/2 trial of mirdametinib in low-grade gliomaN/A
2021-07-22 02:35 ESTNewsDosing underway in Precision Bio, SpringWorks Phase 1/2a PBCAR269A/nirogacestat combo trialN/A
2021-07-22 02:10 ESTNewsSpringWorks issued mirdametinib related U.S. composition of matter patentN/A
2021-07-22 02:09 ESTNewsGoldman Sachs raises price target for SpringWorks; sees 62% upsideN/A
2021-05-06 19:44 ESTNewsSpringWorks Therapeutics EPS misses by $0.11N/A
2021-05-06 19:44 ESTNewsSpringWorks Therapeutics in-licenses rights to TEAD inhibitor portfolio in solid tumorsN/A
2021-04-15 08:22 ESTNewsSpringWorks Therapeutics: Pfizer Spin-Off With Late-Stage Oncology PipelineN/A
2021-04-13 02:32 ESTNewsAllogene and Springworks starts dosing in early-stage multiple myeloma studyN/A
2021-04-01 23:40 ESTNewsDosing underway in SpringWorks Therapeutics' nirogacestat combo study in multiple myelomaN/A
2021-03-29 18:24 ESTNewsPersonalis inks deal with Mapkure for BGB-3245 developmentN/A
2021-03-01 16:31 ESTFinancialsCompany financials have been released.Neutral
2021-02-26 07:39 ESTNewsSpringWorks’ mid-stage neurofibromatosis trial shows 50% objective response rateN/A
2021-02-26 04:45 ESTEarnings EstimateAn EPS average of -$2.66 is estimated for the 2022 year.Sell
2021-02-26 04:45 ESTEarnings EstimateAn EPS average of -$0.54 is estimated for the quarter ending on June 30, 2021.Sell
2021-02-26 04:45 ESTAnalyst RatingThe Analyst Target Price has increased from $92.4 to $105.Buy
2021-02-25 10:09 ESTNewsSpringWorks Therapeutics EPS beats by $0.31, beats on revenueN/A
2021-01-26 00:39 ESTAnalyst RatingThe Analyst Target Price has increased from $87.8 to $92.4.Buy
2021-01-22 20:28 ESTNewsSpringWorks Therapeutics perks up as Barclays raises PT to $92N/A

About SpringWorks Therapeutics, Inc (SWTX):

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Quotes by TradingView

See Advanced Chart

General

  • Name SpringWorks Therapeutics, Inc
  • Symbol SWTX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 78
  • Fiscal Year EndDecember
  • IPO Date1987-06-05
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryCommodity Chemicals
  • Web URLhttp://www.springworkstx.com
View More

Valuation

  • Trailing PE 15.29
  • Price/Sales (Trailing 12 Mt.) 92.61
  • Price/Book (Most Recent Quarter) 6.58
  • Enterprise Value Revenue 90.3
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.20
  • Next Year EPS Estimate -$2.66
  • Next Quarter EPS Estimate -$0.50
  • Profit Margin -130%
  • Operating Margin -132%
  • Return on Assets -6%
  • Return on Equity -10%
  • Revenue 35 million
  • Earnings Per Share -$44.68
  • Revenue Per Share $0.81
  • Gross Profit 35 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 3.4 billion
  • EBITDA -38141000
  • Analyst Target Price $105
  • Book Value Per Share $7.80
View More

Share Statistics

  • Shares Outstanding 48.77 million
  • Shares Float 25.35 million
  • % Held by Insiders 1374%
  • % Held by Institutions 78.03%
  • Shares Short 3.29 million
  • Shares Short Prior Month 3.04 million
  • Short Ratio 12.81
  • Short % of Float 21%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • 52 Week High $96.48
  • 52 Week Low $22.33
  • 50 Day Moving Average 83
  • 200 Day Moving Average 67.15
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

SpringWorks Therapeutics, Inc (SWTX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

SpringWorks Therapeutics, Inc (SWTX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A$0.30$0.08280%
2020-09-302020-11-12$N/A-$0.44-$0.43-1.77%
2020-06-302020-08-12$N/A-$0.41-$0.35-18.61%
2020-03-312020-05-12$N/A-$0.33-$0.354.41%
2019-12-312020-03-12$N/A-$0.39-$0.32-21.88%
2019-09-302019-11-12$N/A-$0.37-$0.419.02%

SpringWorks Therapeutics, Inc (SWTX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

SpringWorks Therapeutics, Inc (SWTX) Chart:

SpringWorks Therapeutics, Inc (SWTX) News:

Below you will find a list of latest news for SpringWorks Therapeutics, Inc (SWTX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

SpringWorks Therapeutics, Inc (SWTX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-1722.50CALL0 0198.45TRUE00
2024-05-17250CALL0 0167.06TRUE00
2024-05-17300CALL0 0126.57TRUE00
2024-05-17350CALL0 0101.26TRUE00
2024-05-17404.2CALL0 10965.63TRUE00
2024-05-17453CALL0 10171.35TRUE00
2024-05-17501.25CALL0 490FALSE00
2024-05-17550.6CALL37 673.09FALSE0.60
2024-05-17600.73CALL0 5490FALSE00
2024-05-17650.55CALL0 1100FALSE00
2024-05-17701.05CALL0 30FALSE00
2024-05-1722.50PUT0 00FALSE00
2024-05-17250.4PUT0 10FALSE00
2024-05-17300.3PUT0 150FALSE00
2024-05-17350.1PUT1 565.15FALSE0.10
2024-05-17402PUT0 54475.85FALSE00
2024-05-17455.2PUT0 592.9FALSE00
2024-05-17500PUT0 080.08TRUE00
2024-05-17550PUT0 073.05TRUE00
2024-05-17600PUT0 078.37TRUE00
2024-05-17650PUT0 0169.59TRUE00
2024-05-17700PUT0 0189.19TRUE00
2024-06-217.50CALL0 0240.79TRUE00
2024-06-21100CALL0 0198.1TRUE00
2024-06-2112.50CALL0 0223.65TRUE00
2024-06-21150CALL0 0192.54TRUE00
2024-06-2117.50CALL0 0139.96TRUE00
2024-06-212014.5CALL0 10125.19TRUE00
2024-06-2122.512.4CALL0 3139.27TRUE00
2024-06-212524.6CALL0 13125.43TRUE00
2024-06-213014.87CALL0 599.89TRUE00
2024-06-213516.1CALL0 39990.17TRUE00
2024-06-21408.9CALL0 34474.19TRUE00
2024-06-21453.04CALL0 6067.32TRUE00
2024-06-21502.7CALL0 225961.88FALSE00
2024-06-21551.55CALL0 205461.75FALSE00
2024-06-21600.9CALL0 44769.39FALSE00
2024-06-21651.7CALL0 11974.04FALSE00
2024-06-21700.2CALL0 200FALSE00
2024-06-21750.85CALL0 20FALSE00
2024-06-217.50PUT0 00FALSE00
2024-06-21100PUT0 00FALSE00
2024-06-2112.50PUT0 00FALSE00
2024-06-21150.45PUT0 20FALSE00
2024-06-2117.50.66PUT0 10FALSE00
2024-06-21200.8PUT0 10FALSE00
2024-06-2122.51.05PUT0 30FALSE00
2024-06-21251.35PUT0 10FALSE00
2024-06-21300.5PUT0 2877.87FALSE00
2024-06-21351.3PUT4 980.06FALSE1.30
2024-06-21403.3PUT0 3677.54FALSE00
2024-06-21455.7PUT0 8269.83FALSE00
2024-06-21509PUT0 473.33TRUE00
2024-06-215510.3PUT0 560.57TRUE00
2024-06-216012.6PUT0 1670.66TRUE00
2024-06-21650PUT0 0102.4TRUE00
2024-06-21700PUT0 082.41TRUE00
2024-06-21750PUT0 091.91TRUE00
2024-09-20200CALL0 0105.55TRUE00
2024-09-2022.50CALL0 094.22TRUE00
2024-09-202524.25CALL0 190.94TRUE00
2024-09-203017CALL0 382.31TRUE00
2024-09-20350CALL0 068.84TRUE00
2024-09-20409.6CALL0 365.08TRUE00
2024-09-20457.9CALL0 27666.69TRUE00
2024-09-20506.4CALL0 2268.41FALSE00
2024-09-20554.45CALL0 2459.47FALSE00
2024-09-20605.3CALL0 1563.45FALSE00
2024-09-20650CALL0 058.04FALSE00
2024-09-20704CALL0 5859.92FALSE00
2024-09-20750CALL0 070.58FALSE00
2024-09-20200.3PUT0 10FALSE00
2024-09-2022.50.4PUT0 1129.51FALSE00
2024-09-20251.1PUT0 15111.07FALSE00
2024-09-20301.35PUT0 1082FALSE00
2024-09-20352.6PUT0 1271.39FALSE00
2024-09-20404.5PUT0 368.53FALSE00
2024-09-20456.5PUT0 372.21FALSE00
2024-09-20509.3PUT0 1065.5TRUE00
2024-09-20550PUT0 063.74TRUE00
2024-09-20600PUT0 060.34TRUE00
2024-09-20650PUT0 064.46TRUE00
2024-09-20700PUT0 068.7TRUE00
2024-09-20750PUT0 056.69TRUE00
2024-12-2022.50CALL0 083.41TRUE00
2024-12-20250CALL0 078.94TRUE00
2024-12-20300CALL0 077.65TRUE00
2024-12-20350CALL0 064.4TRUE00
2024-12-20400CALL0 068.95TRUE00
2024-12-20459.33CALL0 066.34TRUE00
2024-12-20500CALL0 063.8FALSE00
2024-12-20550CALL0 061.41FALSE00
2024-12-20600CALL0 065.6FALSE00
2024-12-20650CALL0 060.3FALSE00
2024-12-2022.50PUT0 0103.36FALSE00
2024-12-20250PUT0 087.7FALSE00
2024-12-20300PUT0 070.52FALSE00
2024-12-20350PUT0 068.23FALSE00
2024-12-20400PUT0 070.58FALSE00
2024-12-20458.3PUT26 125664.69FALSE-0.2-0.02
2024-12-20500PUT0 066.71TRUE00
2024-12-20550PUT0 062.72TRUE00
2024-12-20600PUT0 060.21TRUE00
2024-12-20650PUT0 059.43TRUE00
2025-01-17300CALL0 070.87TRUE00
2025-01-17350CALL0 069.63TRUE00
2025-01-17400CALL0 066.5TRUE00
2025-01-17450CALL0 065.66TRUE00
2025-01-17500CALL0 063.8FALSE00
2025-01-17550CALL0 059.28FALSE00
2025-01-17300PUT0 066.49FALSE00
2025-01-17350PUT0 064.5FALSE00
2025-01-17400PUT0 066.11FALSE00
2025-01-17459.1PUT0 81765.17FALSE00
2025-01-17500PUT0 066.35TRUE00
2025-01-17550PUT0 060.68TRUE00

Latest SWTX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST8$20.08
Jun 13, 2022 7:59 PM EST78$20.09
Jun 13, 2022 7:59 PM EST9$20.085
Jun 13, 2022 7:59 PM EST91$20.09
Jun 13, 2022 8:41 PM EST1$20.85

SpringWorks Therapeutics, Inc (SWTX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000110465920066080/0001104659-20-066080-index.htm
2019-07-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1773427/000000000019010743/0000000000-19-010743-index.htm
2019-07-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1773427/000000000019011747/0000000000-19-011747-index.htm
2019-08-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1773427/000000000019012902/0000000000-19-012902-index.htm
2019-09-03UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1773427/000000000019013062/0000000000-19-013062-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000007800319000070/0000078003-19-000070-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000007800319000071/0000078003-19-000071-index.htm
2020-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1773427/000007800320000009/0000078003-20-000009-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000089924319023429/0000899243-19-023429-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000089924319023430/0000899243-19-023430-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000089924319023677/0000899243-19-023677-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000089924319023936/0000899243-19-023936-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000089924320013997/0000899243-20-013997-index.htm
2019-09-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1773427/000092189519002444/0000921895-19-002444-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1773427/000092189520000536/0000921895-20-000536-index.htm
2019-09-25SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1773427/000094787119000699/0000947871-19-000699-index.htm
2020-10-14SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1773427/000094787120000794/0000947871-20-000794-index.htm
2019-10-29S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1773427/000110465919057296/0001104659-19-057296-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000110465919062126/0001104659-19-062126-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1773427/000110465919062202/0001104659-19-062202-index.htm
2019-11-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465919064757/0001104659-19-064757-index.htm
2019-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465919069637/0001104659-19-069637-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000110465919071063/0001104659-19-071063-index.htm
2020-02-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920010664/0001104659-20-010664-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920011252/0001104659-20-011252-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920029342/0001104659-20-029342-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920029343/0001104659-20-029343-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920029344/0001104659-20-029344-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920029345/0001104659-20-029345-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920029346/0001104659-20-029346-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920033095/0001104659-20-033095-index.htm
2020-03-23S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920037339/0001104659-20-037339-index.htm
2020-04-02DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920042495/0001104659-20-042495-index.htm
2020-04-02DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1773427/000110465920042519/0001104659-20-042519-index.htm
2020-05-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920065399/0001104659-20-065399-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920065405/0001104659-20-065405-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920065406/0001104659-20-065406-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920065407/0001104659-20-065407-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920065411/0001104659-20-065411-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920065412/0001104659-20-065412-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000110465920066080/0001104659-20-066080-index.htm
2020-08-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920090963/0001104659-20-090963-index.htm
2020-08-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000110465920090964/0001104659-20-090964-index.htm
2020-10-06S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1773427/000110465920112645/0001104659-20-112645-index.htm
2020-10-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1773427/000110465920112730/0001104659-20-112730-index.htm
2020-10-08424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1773427/000110465920113419/0001104659-20-113419-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000110465920113428/0001104659-20-113428-index.htm
2019-06-07DRSDraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1773427/000114420419030313/0001144204-19-030313-index.htm
2019-07-22DRS/ADraft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1773427/000114420419035247/0001144204-19-035247-index.htm
2019-07-19DRSLTRCorrespondence Related to Draft Registration Statementhttps://www.sec.gov/Archives/edgar/data/1773427/000114420419035249/0001144204-19-035249-index.htm
2019-08-16S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1773427/000114420419040443/0001144204-19-040443-index.htm
2019-08-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1773427/000114420419040447/0001144204-19-040447-index.htm
2019-08-27CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1773427/000114420419041820/0001144204-19-041820-index.htm
2019-09-03S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1773427/000114420419043091/0001144204-19-043091-index.htm
2019-09-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1773427/000114420419043092/0001144204-19-043092-index.htm
2019-09-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1773427/000114420419043219/0001144204-19-043219-index.htm
2019-09-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044025/0001144204-19-044025-index.htm
2019-09-10CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044173/0001144204-19-044173-index.htm
2019-09-118-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1773427/000114420419044242/0001144204-19-044242-index.htm
2019-09-12S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1773427/000114420419044320/0001144204-19-044320-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044412/0001144204-19-044412-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044413/0001144204-19-044413-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044414/0001144204-19-044414-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044415/0001144204-19-044415-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044417/0001144204-19-044417-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044419/0001144204-19-044419-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044421/0001144204-19-044421-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044423/0001144204-19-044423-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044424/0001144204-19-044424-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044425/0001144204-19-044425-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044427/0001144204-19-044427-index.htm
2019-09-123Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044429/0001144204-19-044429-index.htm
2019-09-13424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1773427/000114420419044571/0001144204-19-044571-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044792/0001144204-19-044792-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044793/0001144204-19-044793-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044794/0001144204-19-044794-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044795/0001144204-19-044795-index.htm
2019-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000114420419044905/0001144204-19-044905-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419045296/0001144204-19-045296-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419045297/0001144204-19-045297-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000114420419045298/0001144204-19-045298-index.htm
2019-10-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000114420419048130/0001144204-19-048130-index.htm
2019-09-24SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1773427/000119312519252375/0001193125-19-252375-index.htm
2019-09-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1773427/000119312519255944/0001193125-19-255944-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1773427/000119312520038108/0001193125-20-038108-index.htm
2020-10-15SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1773427/000119312520270358/0001193125-20-270358-index.htm
2019-09-12CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1773427/000135445719000445/0001354457-19-000445-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1773427/000155837020002563/0001558370-20-002563-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000155837020002567/0001558370-20-002567-index.htm
2020-05-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1773427/000155837020006369/0001558370-20-006369-index.htm
2020-05-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000155837020006378/0001558370-20-006378-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1773427/000155837020010433/0001558370-20-010433-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1773427/000155837020010439/0001558370-20-010439-index.htm
2019-04-12DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1773427/000177342719000002/0001773427-19-000002-index.htm
2019-09-12EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1773427/999999999519002076/9999999995-19-002076-index.htm
2019-06-26SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1773427/999999999719005851/9999999997-19-005851-index.htm
2019-09-05SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1773427/999999999719006703/9999999997-19-006703-index.htm

SpringWorks Therapeutics, Inc (SWTX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of SpringWorks Therapeutics, Inc (SWTX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1374%
Institutional Ownership: 7803%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-09-17Freda C Lewis-HallDirectorBuy50,000.0018.00900,000.004,593,847.00https://www.sec.gov/Archives/edgar/data/1773427/000114420419045298/0001144204-19-045298-index.htm
2019-09-17PFIZER INC10% Share HolderBuy50,000.0018.00900,000.004,593,847.00https://www.sec.gov/Archives/edgar/data/1773427/000007800319000071/0000078003-19-000071-index.htm
2019-09-17Bain Capital Life Sciences Investors, LLC10% Share HolderBuy150,000.0018.002,700,000.007,281,307.00https://www.sec.gov/Archives/edgar/data/1773427/000089924319023936/0000899243-19-023936-index.htm
2019-09-17ORBIMED ADVISORS LLC10% Share HolderBuy275,000.0018.004,950,000.007,406,307.00https://www.sec.gov/Archives/edgar/data/1773427/000114420419045296/0001144204-19-045296-index.htm
2019-09-17STEPHEN P SQUINTODirectorBuy275,000.0018.004,950,000.007,406,307.00https://www.sec.gov/Archives/edgar/data/1773427/000114420419045297/0001144204-19-045297-index.htm